Welcome to Shanghai Kuanta Biomedicine science and technology Co., Ltd. official website!

PRODUCTS 

pharmaceutical intermediates

Pesticide intermediates

NEWS 

Shenzhen Continues to Explore the Development Opportunities and Paths of Internationalization of Biomedicine

[China Pharmaceutical Network Industry News] In recent years, Shenzhen has attached great importance to fostering the development of biological and life and health industries. During the process of industrial transformation, Pingshan District has seized the opportunity and the bio-pharmaceutical industry has become one of the pillar industries in Pingshan. In addition, at present, Shenzhen Bio-pharmaceutical Innovation Industrial Park has also introduced two bio-industry common service platforms—the Guangdong Provincial Medical Device Quality Supervision and Inspection Institute and the China-Israel Innovation and Technology Service Center to promote the healthy development of the bio-pharmaceutical industry.

On September 22, the “Shenzhen Pingshan International Biopharmaceutical Industry Innovation Development Summit” co-sponsored by the Shenzhen Municipal Council for the Promotion of International Trade and Pingshan District Government was held in Pingshan District, Shenzhen. Seven academicians and well-known experts and scholars from home and abroad will visit the scene to discuss the development opportunity and path of Shenzhen's biopharmaceutical investment under the background of Guangdong, Hong Kong and Macao Bay Area.

In recent years, Shenzhen has attached great importance to nurturing the development of biological and life and health industries. During the process of industrial transformation, Pingshan District has seized the opportunity and the bio-pharmaceutical industry has become one of the pillar industries in Pingshan and will form 100 billion in the “Thirteenth Five-Year Plan” period. The scale of production value.

The arrival of the Pingshan International Biopharmaceutical Industry Innovation and Development Summit in Shenzhen will play an important platform role for Pingshan and even Shenzhen to integrate the high-end resources of the entire industry chain in the biological field and promote the exchange of biotechnology at home and abroad.

Biomedical engineering cross-border fusion

Realize the international development of the industry

The construction of Guangdong, Hong Kong, and Macao Bay Area puts forward higher requirements for industrial development, not only to improve resource allocation capabilities, leading functions of the industrial chain, but also to further enhance the ability of the external economy.

The Shenzhen Pingshan International Biopharmaceutical Industry Innovation and Development Summit was held to bring together experts and scholars from around the world in the field of biomedicine and the cutting-edge wisdom of elites from all walks of life to in-depth explore innovative ideas in the development strategy of the Guangdong, Hong Kong and Macau Bay Area, and accelerate the cross-border biomedical engineering. Integrate, advance layout, realize biomedical industry scale, agglomeration and international development.

Including American Academy of Engineering, Medical School, Academician of the Third World Academy of Sciences, Chinese Academy of Engineering Foreigner Cato T. Laurencin (Gatto Laurentson), Chinese Academy of Engineering Ding Jian, Chinese Academy of Sciences Yan Deyue, Chinese Academy of Sciences Zhang Xuemin, American Academy of Engineering Sun Yongkui Academician Zhao Xiaobin, member of the Royal Society of Chemistry, Han Zhongchao, member of the French Academy of Science and Technology, seven academicians, and a group of famous experts and scholars will discuss the development of the biomedical industry. In addition, there are 8 teams participating in the summit road show, which will bring the latest research results in the development of the next generation of peptide antibiotics, the precise detection technology of tumors based on exosomes, the research and development and industrialization of articular cartilage, and other biological medicine.

Before this, the Shenzhen government has successfully hosted the 6th Biology Exhibition and the 4th "Shenzhen International BT Leaders Summit". Each year, the exhibition attracts hundreds of well-known domestic and foreign companies, research institutions and experts and scholars from around the world to participate in the integration. Biological resources and the promotion of exchanges and cooperation in biotechnology have played an important role.

During the "Thirteenth Five-Year" period, the biological industry

The base will reach a scale of 100 billion yuan

In recent years, Shenzhen has attached great importance to fostering the development of biological and life and health industries. During the process of industrial transformation, Pingshan District has seized the opportunity and the bio-pharmaceutical industry has become one of the pillar industries in Pingshan.

The Shenzhen National Biological Industry Base in Pingshan District is one of the first batch of three bio-industry bases approved by the National Development and Reform Commission in 2005. The base area is 3.29 square kilometers. Over the years, the base has insisted on independent innovation as the leading strategy for industrial development. More than 70 talent teams at all levels, including the academician team and the “Thousand Talents Program” team, have been introduced to focus on cultivating market leaders with leading technology.

The national bio-industry base adopts the “triple jump” model of incubation, acceleration, and land supply, and forms a full-industry chain support system from enterprise incubation to project research and development, from results transformation to market expansion, and from financial support to listing financing.

As the landmark supporting facility of the Shenzhen National Bio-industry Base, the Shenzhen Bio-pharmaceutical Innovation Industry Park is a large-scale industrial carrier for accumulating high-quality resources in the field of bio-medicine and promoting the rapid expansion of high-growth SMEs, and is currently the city of Shenzhen. A few specialized bio-industrial parks that meet the GMP construction standards have been invested by Shenzhen Investment Holdings Co., Ltd. with a total investment of 700 million yuan, covering an area of ​​123,400 square meters and a total construction area of ​​220,000 square meters, with a total of 10 buildings.

At present, Shenzhen Biopharm Innovating Industrial Park has introduced two generic service platforms for the bio-industry - the Guangdong Medical Device Quality Supervision and Inspection Institute and the China-Israel Technology Innovation Service Center. The Guangdong Medical Device Quality Supervision and Inspection Institute is a public-affiliated public hospital management institution under the Guangdong Provincial Food and Drug Administration. It is the only national-level medical device quality inspection institute designated by the State Food and Drug Administration in South China and is expected to be completed in the first quarter of 2018. Construction. The China-Israel Innovation and Technology Service Center, operated by Israel’s Outstanding Technology Service Agency, will create an exemplary platform for the introduction of Israeli high-end industrial projects, transfer of technology, and transformation of scientific and technological achievements in the Pearl River Delta region and even the entire country, and the introduction of Israel’s outstanding industrial service companies. Technology service and achievement transformation companies and professional incubator operators have promoted the transformation of high-quality biomedical projects in Pingshan.

At present, Pingshan's biopharmaceutical industry has gathered more than 120 biomedical, medical device companies and service organizations. Among them, there are more than 50 biopharmaceutical companies, including Microchip Bio, a world top 500 enterprise engaged in the development of a class of innovative drugs, and Heshuntang, which is engaged in the development of fine traditional Chinese medicine. There are more than 40 medical device companies, including Libang Precision Instrument Co., Ltd., which is engaged in multi-parameter monitoring and in vitro diagnostic equipment research and development, and a new industrial biology company specializing in the development of clinical test and analysis instruments.

During the “Thirteenth Five-Year Plan” period, the bio-industry base will introduce a number of major projects with a total investment of over 15 billion yuan, forming an eastern bio-industrial cluster with a production scale of 100 billion yuan.

Links 7 academicians attend

American Academy of Engineering, Medical College, Academician of the Third World Academy of Sciences, Foreign Academician of Chinese Academy of Engineering

Cato T.Laurencin (gatto Laurentson)

World-famous biomaterial science and engineering expert, bone surgeon, founder of regeneration engineering. His outstanding achievements in engineering science and technology have won the Clinton Presidential Award (1995), President Obama Award (2010), Millennium Foundation "Technology Leader Award" (2001) and so on. Its first artificial ligament was selected as "Scientific American" and "Global Technology Leader 50" (2007).

Academician of the Chinese Academy of Engineering

Now he is the dean of the College of Pharmacy, University of Chinese Academy of Sciences, and the director of the Academic Committee of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Its focus has focused on the discovery of new anti-cancer targeting molecules, the discovery of new mechanisms of action, and the identification of new biomarkers for this systematic research goal, and has made important progress in the study of molecularly targeted anti-cancer drugs.

Academician of Chinese Academy of Sciences Yan Deyue

Polymer chemists have long studied non-steady state polymerization kinetics theory, polymer conformation statistics, molecular design of hyperbranched polymers, and supramolecular self-assembly of irregular polymers. Macromolecular-scale supramolecular molecules were discovered in the laboratory. Self-assembly phenomenon.

Academician of Chinese Academy of Sciences Zhang Xuemin

He has been the chief scientist of the National Major Scientific Research Plan Project, an academic leader of the “Tumor Biology” innovation research group of the State Fund Committee, and a member of the State Council Committee on Food Safety Special Committee. He has long been engaged in the research on the relationship between inflammation and tumorigenesis. His major research results have been Published in international academic journals such as Nature Immunology and Nature Medicine. He won the "National Natural Science Award" and "Tan Jiaxuan Life Science Achievement Award".

American Academy of Engineering Sun Yongkui

Ph.D. in Chemistry from California Institute of Technology. He received the AstraZeneca Green Chemistry and Engineering Excellence Award from the British Chemical Engineers Association in 2005 and the Presidential Green Chemistry Challenge Award in 2005 and 2006 (US Environmental Protection Agency, Washington, DC).

Academician of Royal Society of Chemistry Zhao Xiaobin

He is currently a Fellow of the Royal Society of Chemistry, a Chartered Chemist, a member of the Materials, Minerals and Mining Association, a member of the British Materials Research Institute, and a member of the American Biomaterials Association. He has published 45 scientific papers and articles and holds a number of international patents. His main research direction is the bioremediation of biomaterials.

Academician of French National Academy of Science Han Zhongchao

He is mainly engaged in the research and development of blood vessel cell molecular biology and biotechnology. He has achieved many international leading academic achievements in the research of stem cells, megakaryocytes and platelets, angiogenesis and its control, and chemokines.

Add: Room 1610, No. 2, Lane 789, Tianzhu Road, Jiading New City, Shanghai, China

Contact: Manager Feng   Mobile:+86-13916443339 

E-mail:feng1150@aliyun.com

Zip code:201810

Tel:+86-21-69580854 Fax:+86-21-51062356

URL:www.kuantianpharm.com

Copyright(C)2018, Shanghai Kuanta Biomedical Technology Co., Ltd. All Rights Reserved. Supported by ChinaChemNet ChemNet Toocle Copyright Notice 备案字号:沪ICP备18023014号